⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
globenewswire.com
OTLK
OTLKW
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
OTLKW
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
globenewswire.com
OTLK
OTLKW